OGA and myocardial infarction: For example, increasing O-GlcNAc levels in cardiac myocytes by treatment with GlcN, PUGNAc or NAG-Bt and NAG-Ae, highly selective O-GlcNAcase inhibitors, protects against ischemia-reperfusion injury [24]–[29] and ischemic injury related to myocardial infarction [30].